The platform includes a built-in connectivity gateway through Iris for standalone devices such as IV pumps, capnography, wireless functionality as well as flexible measurement expansion through Masimo Open Connect.
“With the new FDA clearance for Root, Masimo is eager to help U.S. clinicians usher in a new era of patient care and improved patient safety with a platform that should measurably improve the performance and cost curve,” said Joe Kiani, founder and CEO of Masimo in a news release.
Masimo is a developer of noninvasive monitoring technologies.
More Articles on Quality:
Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough
